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Paul J. Martin,1 Carlos R. Bachier,2 Hans-Georg Klingemann,3 Philip L. McCarthy,4
Paul Szabolcs,5 Joseph P. Uberti,6 Michael W. Schuster,7 Daniel Weisdorf,8 Nelson J. Chao,5
Partow Kebriaei,9 Elizabeth J. Shpall,9 Margaret L. MacMillan,8 Robert J. Soiffer10Currently, no agents are approved by the United States Food and Drug Administration (FDA) for either pre-
vention or treatment of acute graft-versus-host disease (aGVHD). Formal precedents establishing a compar-
ative basis for assessing the efficacy and safety of new investigational agents are still lacking. As a step toward
addressing this problem, a panel of experts met on 2 occasions to reach consensus on recommendations for
terminology describing a clinically meaningful primary endpoint in studies assessing treatment for aGVHD.
The panel recommended terminology for ‘‘very good partial response’’ (VGPR) that includes both diagnostic
and functional criteria. The central hypothesis leading to this proposal is that the potential harm of giving
more treatment than needed to produce or maintain complete response exceeds the harm of slight under-
treatment that may be associated with less than complete response. VGPR clearly cannot be used as the sole
outcome measure in GVHD treatment trials, and must be considered in the context of survival and safety.
The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its
use has been validated through experience.
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Progress in the treatment of acute graft-versus-
host disease (aGVHD) requires appropriate planning,
conduct, and interpretation of results of clinical trials.
Most of the historical studies that have assessed the ef-
ficacy of treatment for aGVHDwere sponsored by ac-
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6/j.bbmt.2009.03.012management of GVHD has been based largely on
institutional and physician experience, with some con-
sideration of evidence from the literature [1]. Cur-
rently, no agents are approved by the United States
Food and Drug Administration (FDA) for either pre-
vention or treatment of aGVHD. Numerous clinical
trials with GVHD-related endpoints are in progress,
although very few phase III studies have a primary end-
point directly related to treatment of GVHD. Because
the field lacks formal precedents that could provide
a consistent comparative basis for assessing the efficacy
and safety of new investigational agents, the design of
trials to demonstrate overall clinical benefit with statis-
tical certainty remains extremely difficult both for
academic and industry sponsors.
The challenges inherent in assessing response to
treatment of aGVHD in the context of the complex
and variable manifestations of the disease suggest the
need for a more standardized and clinically meaningful
approach to clinical trial design [2]. Such guidance
would benefit regulatory agencies, the transplant com-
munity, sponsors, and ultimately the patients forwhom
these new treatments are intended. A similar effort for
chronic GVHD (cGVHD) has resulted in the publica-
tion of a series of consensus documents describing uni-
fied recommendations for the diagnosis, staging, and
response criteria for cGVHD. This effort was777
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sensus Development Project on Criteria for Clinical
Trials in Chronic Graft-versus-Host Disease [3-8].
As an initial step in addressing clinical trial design
for aGVHD, a panel of experts met on 2 occasions to
reach consensus on recommendations for terminology
describing a clinically meaningful primary endpoint in
studies assessing treatment for aGVHD. The goal was
to develop criteria for treatment success that are suffi-
ciently flexible to allow interpretation according to in-
stitutional protocol and physician experience, whereas
minimizing subjectivity and bias to achieve sufficient
consistency of response for regulatory approval.Overview of Regulatory Climate in Oncology
and Autoimmune Disease
A regulatory approval pathway is clearly needed for
products intended for treatment of aGVHD.Such path-
ways have already been established for products in other
therapeutic areas such as oncology and autoimmune dis-
eases. The overall goal of clinical trials is to provide
direct evidence of clinical benefit for a treatment. Al-
though improved survival would provide persuasive
evidence of benefit in a GVHD treatment trial, experi-
ence has shown that successful control of GVHD does
not necessarily lead to improved survival. For example,
a recent study by Levine et al. [9] showed that despite
impressive differences in day 28 response rates after
treatment of aGVHD with etanercept plus steroids
compared to steroids alone, survival differenceswereob-
served among patients who had related donors, but not
among those with unrelated donors. Among patients
with related donors, the difference in survival between
the 2 treatment groupswasmuch smaller than the differ-
ence in response rates. In GVHD treatment trials,
differences in themagnitude of response and survival ef-
fects are likely related to complications such as infection,
regimen-related toxicity, recurrentmalignancy, andpre-
existing conditions unrelated to GVHD [10]. Even
though most GVHD treatments are not likely to pro-
duce a survival benefit, survival remains as an appropri-
ate secondary endpoint to consider in aGVHD
treatment trials.
Although prolonged survival is considered the
most reliable endpoint with clinical benefit in oncol-
ogy trials, the FDA has accepted nonsurvival endpoints
such as tumor response rates as the basis for both reg-
ular and accelerated approval. In studies of patients
with serious or life-threatening diseases, accelerated
approval status permits the use of nonsurvival end-
points if they are reasonably likely to provide clinical
benefit. Postmarketing studies are usually required to
confirm clinical benefit [11]. From January1990 to
November 2002, 68% (39 of 57) of regular approvals
and all 14 accelerated approvals for oncology drugs
were based on nonsurvival endpoints [11].Regulatory approval pathways based on nonsurvival
endpoints have been established for products in auto-
immune diseases that have some similarity to GVHD,
including Crohn’s disease, rheumatoid arthritis, and
systemic lupus erythematosis (SLE). For these chronic
inflammatory diseases characterized by episodes of
flares and remissions, the goals of treatment are to con-
trol inflammation and suppress disease activity. The
first biologic (infliximab) for Crohn’s disease was ap-
proved in 1998 for reduction of signs and symptoms
in patients with moderate to severe active disease. In
2002, a supplemental filing was approved for inducing
and maintaining clinical remission of Crohn’s disease
[12]. Thus, infliximab was first approved based on in-
duction of clinical response, whereas repeated therapy
and maintenance of remission was assessed in a subse-
quent trial [13,14].
Treatment success in clinical studies of autoim-
mune diseases is not predicated on producing
complete response (CR) or remission, but on demon-
strating improvement in a validated score or index
based on a set of established measures of activity in dis-
eases such as rheumatoid arthritis [15], SLE [16,17],
and Crohn’s disease [18]. These indices have been pe-
riodically reviewed and updated as better understand-
ing of disease pathophysiology and new treatments
evolve. A disease index or score, however, might not
be appropriate for treatment trials in aGVHD, because
expectations for aGVHD differ from those for chronic
autoimmune diseases. In autoimmune disease, mortal-
ity is not a key issue, whereas death is an appreciable
risk with GVHD. Furthermore, a disease activity score
is applicable for extended periods of time in patients
with autoimmune diseases, but for only a short period
time in patients with aGVHD. Typically, GVHD has
1 of 3 outcomes: death, progression to cGVHD, or
complete resolution within a period of 4 to 10 weeks.
In most cases, manifestations do not persist for longer
periods of time without progression to cGVHD.
Therefore, control of GVHD manifestations mea-
sured primarily as the response and secondarily as
the durability of the response might have the greatest
impact in determining these 3 possible outcomes.Challenges Facing aGVHDTreatment Protocols
The close relationship between aGVHD and
cGVHD and the lack of an accepted severity index
complicate the measurement of outcomes in GVHD
treatment trials. The introduction of nonmyeloabla-
tive conditioning regimens has highlighted some of
the difficulties in distinguishing aGVHD and cGVHD
[19]. Although aGVHD is often associated with the
development of cGVHD, experts agree that aGVHD
and cGVHD should be viewed as separate diseases, de-
spite the extensive overlap in signs, symptoms, and
management strategies [20-22]. Currently, no single
Table 1. Historical Endpoints in Treatment Trials for aGVHD
Study Agents Tested Primary EndPoint Timing of Assessment
Levine et al 2008 [9] Etanercept in combination with steroids Complete response Day 28
Alousi et al 2008 [47] Etanercept, mycophenolate mofetil, denileukin diftitox, or
pentostatin in combination with steroids
Complete response Day 28
Hockenbery et al 2007 [38] Oral beclomethasone in combination with steroids Time to treatment failure Day 50
Lee et al 2004 [46] Daclizumab in combination with steroids Decrease by 1 grade Day 42
Cragg et al 2000 [39] Antithymocyte globulin in combination with steroids Complete or partial response Day 42
Martin et al 1996 [36] CD5-specific immunotoxin in combination with steroids Complete response Day 42
aGVHD indicates acute graft-versus-host disease.
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severity of skin, liver, and gastrointestinal tract in-
volvement in aGVHD, although most institutions ac-
cept and use the Seattle grading system [23] modified
to omit performance criteria, the consensus criteria ad-
justed for skin, liver, and gut abnormalities caused by
complications other than GVHD [24], or the Interna-
tional Bone Marrow Transplant Registry grading sys-
tem [25] to assess the peak severity of GVHD. These
scales represent static measurements that do not neces-
sarily correlate with treatment outcome or mortality
[26].
In clinical trials, the assessment of response to
treatment requires comparison between 2 sets of mea-
surements—baseline and a designated time of end-
point measurement. In some studies, a change of
GVHD grade has been used to assess response. One
problem with this approach is that trivial changes in
GVHD manifestations can cause a change of grade
that should not be scored as success in a clinical trial
(eg, a decrease in body surface area affected by rash
from 55% to 45%, corresponding to a decrease from
grade II GVHD to grade I GVHD). In principle,
this problem can be circumvented by defining the end-
point as CR or a 2-grade reduction, rather than
a 1-grade reduction. As an alternative, a GVHD activ-
ity index (GVHD AI) that predicts nonrelapse mortal-
ity (NMA) at day 200 among patients with GVHD
could be used to measure response in GVHD trials
[27]. This index includes weighted consideration of
the total serum bilirubin concentration, oral intake,
need for treatment with prednisone, and overall per-
formance score. A disadvantage of this index, however,
is that the bilirubin and performance components are
not necessarily related to GVHD, although it should
be noted that the original description of the GVHD
grading scale included undefined criteria of ‘‘mild,’’
‘‘moderate,’’ or ‘‘extreme’’ decrease in clinical perfor-
mance [23,28]. Later scales omitted these less precise
performance criteria.
The eligibility criteria for enrollment in GVHD
treatment trials are often specified according to the
grade of GVHD, but the decision to treat aGVHD
does not correspond completely with the overall grade
of the disease. In general, a ‘‘watch and wait’’ approach
is taken with patients with grade I aGVHD, but insome cases, it may be justified to treat grade I
GVHD if clinical circumstances offer reasons to ex-
pect rapid progression to more severe disease. Treat-
ment is generally indicated for patients with grades II
to IV disease, although grade II GVHD can leave
room for clinical judgment [29]. For example, stable
GVHD with mild rash involving more than 50% of
the body surface without liver or gastrointestinal in-
volvement does not necessarily require systemic treat-
ment.Recommendations for Terminology
Characterizing Treatment Success
The design of clinical trials, whether sponsored by
academic institutions or industry, should be guided by
regulatory principles as set forth in the FDA Good
Clinical Practice guidelines and Title 21 of the Code
of Federal Regulations, Part 314.126 [30]. In part, un-
biased compilation and reporting of data should be
based on selection of a primary endpoint that demon-
strates clinical benefit; with adequate statistical power
to discriminate between study arms for the primary
endpoint [31].
A review of selected randomized trials for the treat-
ment of aGVHD shows variation of primary endpoints
and timing of assessment (Table 1). Although a CR,
defined as resolution of all signs and symptoms of
aGVHD, might represent the ultimate goal for indi-
vidual patients, the consensus group agreed that CR
may be too stringent as a primary endpoint in treat-
ment trials. Protocols that seek complete disappear-
ance of all GVHD manifestations as a primary
endpoint may actually discourage or delay appropriate
tapering of concomitant steroid treatment among pa-
tients withGVHD. At the same time, the group agreed
that a partial response (PR) is insufficient for approval.
Control of serious GVHD manifestations with some
durability to permit reduction in steroid doses or other
immunosuppressive therapy may reflect the true clini-
cal goals of successful therapy.
The group sought to initiate an iterative process
that would identify a primary clinical trial endpoint to
permit better comparisons between treatment arms.
The term ‘‘very good partial response’’ (VGPR) has
been used to indicate a response that approximates
Table 2. Consensus Terminology Describing Very Good
Partial Response for acute graft-versus-host disease
 Skin
o No rash, or residual erythematous rash involving <25% of the body
surface, without bullae (residual faint erythema and
hyperpigmentation do not count)
 Liver
o Total serum bilirubin concentration <2 mg/dL or <25% of baseline at
enrollment
 Gut
o Tolerating food or enteral feeding
o Predominantly formed stools
o No overt gastrointestinal bleeding or abdominal cramping
o No more than occasional nausea or vomiting
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CR. Precedent for the use of VGPR has been estab-
lished within the oncology community, where the
term is nowan accepted addition to the uniform clinical
response criteria formultiplemyeloma and is used as an
endpoint in clinical trials [32,33]. The International
MyelomaWorking Group introduced VGPR to iden-
tify patients with excellent responses who may have
outcomes similar to those observed among patients
with CR [34]. VGPR differs in a fundamental way
from PR, despite the similarity in terminology for the
2 outcomes. PR indicates an improvement from base-
line and does not consider whether the response ap-
proximates a CR. In contrast, VGPR indicates any
improvement that approximates CR, which would al-
ways qualify as a PR if more than trivial manifestations
of GVHDwere present at baseline, although the crite-
ria for VGPR do not explicitly consider whether the
magnitude of improvement from baseline is sufficient
to qualify as a PR.
The group agreed on working terminology for
VGPR for aGVHD as shown in Table 2. The termi-
nology incorporates both diagnostic and functional
criteria, and is intended for use with adult patients.
The statements are framed generally according to
the acceptable limits of any manifestations that might
be related to GVHD.
Agreement on the terminology describing VGPR
was based on the potential comfort level with contin-
ued tapering of steroid treatment. A degree of subjec-
tivity in assessing functional criteria provides some
flexibility in interpretation. VGPR generally justifies
continued tapering of steroid treatment, whereas PR
might not.
 Skin: the terminology allows active erythematous
rash involving \25% of the body surface area.
Rash that is pink, fading, or turning to brown is
not included in the measurement, because these
findings indicate resolving lesions.
 Liver: the terminology allows for persisting low-
level hyperbilirubinemia that might be related to
antecedent regimen-related hepatotoxicity,concomitant hemolysis, or administration of hepa-
totoxic agents such as voriconazole, cyclosporine,
or total parental nutrition (TPN), or other factors
such as sepsis. A serum total bilirubin concentration
of\2 mg/dL approximates normal values, and a re-
duction to\25% of the baseline concentration pro-
vides strong evidence of progression toward normal
liver function among patients with levels.2mg/dL.
 Gut: criteria in the terminology were selected to in-
dicate that gut function and water resorption in the
colon are approaching normal. These criteria have
some imprecision and rely heavily on patient recall,
rather than measurement of stool volume, but they
can be easily used for outpatients. In certain cases,
it might be necessary to make allowances for the
effects of pretransplant diseases that cause diarrhea.
Several criteria were excluded because they lack
specificity for GVHD or because they are heavily
influenced by physician or institutional preferences.
For example, requiring the absence of parenteral nutri-
tion was considered too stringent, because parenteral
nutrition can be used to supplement oral intake in
some patients who are otherwise doing well or in pa-
tients who have oral intake limited by factors other
than GVHD. The group recognized that special con-
siderations for pediatric patients should include allow-
ances for decreased oral intake attributed to factors
other than GVHD, such as food aversion, gastric hy-
pomotility, or the effects of pretransplant diseases
such as leukodystrophy syndromes. Even though oral
intake at\40% of daily caloric needs has been associ-
ated with a higher risk of mortality [27], the terminol-
ogy does not include a specific level of oral caloric
intake as a criterion for VGPR, because medical re-
cords do not routinely include estimates of oral caloric
needs and oral caloric intake. Stable body weight was
rejected as a criterion, because weight loss can accom-
pany improvement in liver and gut function in patients
with hypoalbuminemia, and overall performance sta-
tus was not included because of lack of specificity for
GVHD.
Timing of Endpoint Measurement
The group endorsed the assessment of response on
day 28 as a conventional time point for the primary end-
point in GVHD treatment trials, because previous
studies have shown that day 28 appears to yield the
best discriminatory data for GVHD response when an
accelerated response to treatment is anticipated
[9,35,36]. Assessment of the primary endpoint at a single
specified time point has the advantage that sample size
can be easily estimated from binomial distributions. An
additional advantage is the simplicity of describing the
clinical benefit for individual patients. Time to event
measurements, however, remain useful in exploratory
phase II studies where the timing of maximal
Biol Blood Marrow Transplant 15:777-784, 2009 781Endpoints for Acute GVHD Trialsdifferences in response rates between groups cannot be
anticipated. Time to event analysis can also be incorpo-
rated as a secondary endpoint in phase III studies.
The use of a specified time point for assessment of
the primary endpoint might depend on whether the
agent is intended for use on a single occasion, on re-
peated occasions as needed, or continuously until ei-
ther response is observed or until it is determined
that a response is not likely. The group concluded
that the clinical benefit of a new investigational agent
should be evaluated first by demonstrating an im-
proved response rate at a single time point, without in-
cluding durability of response as a component in the
primary endpoint. Durability should be included as
a secondary observational endpoint [37,38], so that
the data can be used to construct a hypothesis to be
tested as the primary endpoint in a subsequent trial
to evaluate the benefits and risks of ad hoc variation
in the schedule or dose of administration according
to the initial response. Durability of response, of
course, may be greatly influenced by concomitant ste-
roid treatment or by other therapy.The Challenge of Steroid Management
Because the efficacy of corticosteroids as first-line
treatment for aGVHD has been established [35,39-
44], it would be very difficult to design a clinical trial
without including steroids in the treatment regimen.
Steroids can have many well-recognized side effects,
but the relationship of steroid dose and treatment du-
ration with potential harms has been only partially de-
fined. Endpoint definitions that require CR might
discourage investigators from fulfilling their ethical
mandate to minimize steroid-related side effects by us-
ing the lowest effective steroid dose. Potentially addi-
tive or synergistic side effects between investigational
agent and steroids must be considered in assessing re-
sults of clinical trials. Assessmentsmust account for the
contribution of steroids to the response, particularly in
demonstrating that any favorable treatment effect was
not merely a consequence of longer duration of steroid
treatment or higher cumulative steroid dose in the in-
vestigational arm compared to the control arm. In un-
controlled trials, the effect of steroid treatment on
overall outcome cannot be determined, and this limita-
tion should be acknowledged.
A lack of consensus among investigators and cen-
ters regarding the starting steroid dose and subsequent
rate of taper has caused problems with add-on study
designs. The starting dose of prednisone or methyl-
prednisolone is usually 1 or 2 mg/kg per day, depend-
ing on the severity of GVHD manifestations and the
degree of steroid-related toxicity. The starting dose
is particularly controversial among patients with dif-
ferent subsets of stage II GVHD [45]. Protocols
should allow some degree of case-by-case physiciandiscretionary judgment, because patients vary in their
response to steroids and in their ability to tolerate
steroids.
A crucial question is whether the steroid dose and
the taper schedule should be mandated in the study
protocol—a mandated dose might be beneficial for
the trial, but not for the patient. Another question is
how long to maintain the starting dose before initiat-
ing the taper (eg, 7 days, 14 days) or should this again
be the physician’s decision? Strictly mandated taper
rates are bound to cause protocol deviations, but too
much variation of steroid dose could lead to a regres-
sion to the mean between study arms, which could
dampen the observed contribution of the study prod-
uct to the response.
Protocols should provide guidance regarding the
use of steroids during the trial in an effort to balance
the ideal of minimizing the steroid dose versus the
ideal of standardizing the treatment regimen. In trials
where steroid management is tightly controlled, ste-
roid dose should not be included as a component in
the definition of response for individual patients. In
trials where the steroid management is not tightly con-
trolled (eg, when steroid-sparing claims are being as-
sessed) steroid dose could be incorporated as part of
the primary endpoint. For example, a remission would
have uncertain value if the steroid dose remains at the
starting dose on day 28. On the other hand, excessively
rapid tapering of steroid doses increases the risk of not
having a response at day 28. Limits on themaximum or
minimum steroid doses at specified intervals, and par-
ticularly at the time for assessment of the primary end-
point, may be important for valid comparisons. In
studies where steroid dose is part of the primary end-
point, blinding of the investigational product would
be needed to support the validity of the endpoint.
The management of flares during taper of steroid
doses is an important issue to address in the protocol.
To a large extent, decisions regarding any increase in
steroid dose or resort to other immunosuppressive
agents must be left to the discretion of the physician
who is responsible for the care of the patient. In any
case, the group agreed that a response should not
count in cases where systemic agents other than those
administered at the beginning of enrollment in the trial
were given to control GVHD before the assessment
day designated for the primary endpoint.Safety
Demonstration of the safety of the investigational
agent is an integral part of the clinical trial design. Al-
though most efficacy studies are not powered to prove
the absence of major harmful effects, a statistically sig-
nificant excess of deaths, NRM, recurrent malignancy,
infections, or serious adverse events in the investi-
gational arm would make regulatory approval very
782 Biol Blood Marrow Transplant 15:777-784, 2009P. J. Martin et al.difficult, if not impossible. Safety data between study
arms should be monitored by a Data and Safety Moni-
toringBoard, so that appropriate actions can be taken if
substantial differences are observed between study
arms, as exemplified the study by Lee et al. [46]. Safety
monitoring beyond the date of the primary endpoint
assessment (eg, 3- or 6-month survival with a day 28
primary endpoint) would be important in judging the
clinical value of the primary endpoint.SUMMARY
The following position statement summarizes the
consensus recommendations and opinions regarding
clinical endpoints in treatment trials for aGVHD.Position Statement
A survival difference between the investigational
and control arms of a GVHD trial would provide per-
suasive evidence of clinical benefit, but prior experi-
ence indicates that even large differences in response
rates might not be sufficient to provide a survival ben-
efit among patients with aGVHD. As an alternative,
a VGPR that closely approximates complete resolu-
tion of disease manifestations has considerable appeal
as a primary endpoint in any phase of clinical trials
for treatment of aGVHD (Table 2).
Results of previous studies have suggested that as-
sessment of response at day 28 after starting treatment
is appropriate for the primary endpoint, but later time
points can be a considered. Earlier time points might
not be a sufficient interval for optimal responses, and
substantially later time points carry increasing risks
of confounding by development of cGVHD.
Because treatment agents can be designed for use
on a single occasion, on repeated occasions as needed,
or continuously, durability of response should not be
required as a component in the primary endpoint of
the initial trials, but is an important secondary end-
point for all new therapies. Follow-up trials may be
needed to define the optimal conditions of use and
the associated risks and benefits.
Inclusion of steroid dose as a component in the cri-
teria for VGPR may be considered if results of the
study are intended to support steroid-sparing claims,
if blinding of the investigational product is feasible.
Otherwise, steroid dose should serve as a group assess-
ment rather than an individual patient assessment. If
a study product is highly effective, steroid doses could
be lower in the investigational arm than in the control
arm, but claims of efficacy would not be credible if ste-
roid doses were higher in the investigational arm than
in the control arm. Claims of steroid-sparing benefit
must be supported by demonstrated overall clinical
benefit to ensure that the benefits related to reductionof steroid exposure are not overwhelmed by side effects
of the investigational agent.
VGPR attained after systemic treatment that is not
prescribed by the protocol, and VGPR followed by
death before the day designated for assessment of the
primary endpoint should not be categorized as success
for the primary endpoint. The VGPR category should
allow administration of secondary systemic therapy af-
ter the day designated for assessment of the primary
endpoint, but the proportions of patients needing sec-
ondary therapy and the time distributions of these
events should be included as secondary endpoints.
Protocols should encourage tapering of steroid doses
at a rate that is commensurate with resolution of
GVHD manifestations, to minimize the risk of ste-
roid-related complications. The VGPR category
should allow escalation of steroid doses to regain con-
trol of GVHD before or after assessment of the pri-
mary endpoint, but the frequency of dose escalation
should be included as a secondary endpoint. Protocols
should provide criteria and guidelines for dose escala-
tion and subsequent tapering of steroid doses.Implementation
In clinical practice, either VGPR or CR can justify
gradual withdrawal of immunosuppressive treatment.
The use of VGPR as the primary endpoint in clinical
trials, particularly if it is durable, addresses problems
potentially associated with the use of CR as the pri-
mary endpoint. One concern is that it is not always
possible to determine whether hepatic and gastrointes-
tinal abnormalities are caused by GVHD or other
complications. The use of VGPR as an endpoint
makes some allowance for minor intermittent clinical
abnormalities that might not be caused by GVHD,
whereas the strict use of CR does not. The allowance
for minor clinical abnormalities in VGPR mitigates
the need for potentially arbitrary and subjective down-
grading to account for abnormalities caused by com-
plications other than GVHD. A second concern is
that overzealous immunosuppressive treatment given
to produce CR could have detrimental effects on sur-
vival [10]. The use of VGPR as an endpoint follows
from the belief that the potential harm of giving
more treatment than is really needed to produce or
maintain CR exceeds the harm of slight undertreat-
ment that may be associated with VGPR.
The proposed use of VGPR as the primary end-
point in GVHD treatment trials will remain provi-
sional until its use has been validated through
experience. VGPR clearly cannot be used as the sole
outcome measure in GVHD treatment trials. In real-
ity, multiple endpoints are necessary in evaluating
the overall results of treatment for aGVHD. CR
should be reported to facilitate comparisons with con-
trol groups and results of previous studies. Likewise,
Biol Blood Marrow Transplant 15:777-784, 2009 783Endpoints for Acute GVHD Trialsresults should report flares of aGVHD after CR or
VGPR, need for secondary therapy, cGVHD, NRM,
recurrent malignancy, and overall survival (OS) at
standardized time points (eg, 6 months and 1 year) to
evaluate the overall effects of treatment and to facili-
tate comparisons between studies.
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